Articles tagged with "In Depth"

Sort by

How to solve the funding puzzle…

March 24, 2015
The biggest challenge facing start-ups and science SMEs? It has to be funding. Here, Dr Geoff Davison considers some of the current opportunities available for accessing that all important financing

From villain to hero

March 17, 2015
‘The dose makes the poison’ goes the adage, but could it be so for carbon monoxide and hydrogen sulphide? Could these notorious toxins be used for the treatment of complex...

Is it time to go public?

March 10, 2015
Mike King, an economist based at the National Physical Laboratory explores the benefits that working with a public research establishment can bring for companies.

The difficulties of defining ‘moderate’ drinking

March 5, 2015
Last year, national newspapers ran a story suggesting that drinking a bottle of wine a day isn’t necessarily bad for you. It was based on comments by former World Health...

The big squeeze

March 3, 2015
The physical properties of proteins, so vital for cellular function, are intimately linked to the cellular environment – a very crowded place indeed. But has this relationship been neglected in...

After the vote was over, after the count was done….

February 25, 2015
Dr Geoff Watts, who chaired the Nuffield Council on Bioethics Working Party on mitochondrial transfer, reflects on the run up to the Parliamentary vote that gave it the go ahead,...

Tweaking your ‘procurement engine’ – will your lab benefit?

January 27, 2015
Brand management is giving way to supply chain management in public sector laboratory purchasing models in the drive to manage costs. What can we learn from these changes and in...

The wonder stuff – How peptide hydrogels could change the face of biomedicine

January 20, 2015
With a list of characteristics and applications long enough to make most bioengineers take notice, ultrashort peptide hydrogels are fast becoming the toast of biomedicine. Here, a team from Institute...

A new lease of life

January 13, 2015
When a large scientific company decides to leave a manufacturing or R&D plant, what happens to the state-of-the-art facilities which only these big companies can afford?

The perfect couple

January 8, 2015
The ongoing process of developing new therapeutic drugs has driven research towards a desire to understand drug-target interactions at a molecular level. One group of potential targets attracting a great...

Pin It on Pinterest